STDY OF SIROLIMUS/RAPAMYCIN IN PTS W/ADVNCD PAH REFRACTORY TO CRNTLY AVAIL THRPY

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项初步研究正在进行，以评估西罗莫司在重度晚期肺动脉高压患者中的安全性，这些患者尽管接受了目前最大的治疗，但仍未改善。本研究将在少数晚期PAH患者中测试一种新的生物医学干预（西罗莫司），以评估安全性和有意义的疗效趋势，这可能支持未来开展更大规模的单中心临床试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This pilot study is being done to assess the safety of sirolimus in patients with severe, late-stage pulmonary arterial hypertension who are not improving despite maximal currently available therapy. This study will be testing a biomedical intervention (Sirolimus) that is new to patients with PAH in a small number of patients with advanced disease to assess safety and meaningful trends toward efficacy that would potentially support the future conduct of a larger single-center clinical trial.